TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company specializing in TCR-engineered T cell therapies for cancer treatment, has announced its participation in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference. The company will engage in a fireside chat scheduled for Tuesday, February 25, 2025, at 10:00 a.m. Eastern Time.
Interested parties can access the webcast through the 'Events and Presentations' section on TScan's investor relations website at ir.tscan.com. The presentation recording will remain available for replay on the company's website for 90 days after the event.
TScan Therapeutics (Nasdaq: TCRX), un'azienda biotecnologica in fase clinica specializzata in terapie con cellule T ingegnerizzate TCR per il trattamento del cancro, ha annunciato la sua partecipazione alla 3ª Conferenza Virtuale Annuale sulla Terapia Cellulare H.C. Wainwright. L'azienda parteciperà a una chiacchierata informale programmata per martedì 25 febbraio 2025, alle 10:00 ora orientale.
Le parti interessate possono accedere al webcast attraverso la sezione 'Eventi e Presentazioni' sul sito web delle relazioni con gli investitori di TScan all'indirizzo ir.tscan.com. La registrazione della presentazione rimarrà disponibile per la visione on demand sul sito dell'azienda per 90 giorni dopo l'evento.
TScan Therapeutics (Nasdaq: TCRX), una empresa biotecnológica en fase clínica especializada en terapias con células T ingenierizadas TCR para el tratamiento del cáncer, ha anunciado su participación en la 3ª Conferencia Virtual Anual sobre Terapia Celular H.C. Wainwright. La empresa participará en una charla informal programada para el martes 25 de febrero de 2025, a las 10:00 a.m. hora del este.
Las partes interesadas pueden acceder a la transmisión en vivo a través de la sección 'Eventos y Presentaciones' en el sitio web de relaciones con inversores de TScan en ir.tscan.com. La grabación de la presentación permanecerá disponible para su reproducción en el sitio web de la empresa durante 90 días después del evento.
TScan Therapeutics (Nasdaq: TCRX), 암 치료를 위한 TCR 엔지니어링 T 세포 요법을 전문으로 하는 임상 단계의 생명공학 회사가 H.C. Wainwright 제3회 연례 세포 치료 가상 회의에 참여한다고 발표했습니다. 이 회사는 2025년 2월 25일 화요일 오전 10:00 동부 표준시에 예정된 파이어사이드 채팅에 참여할 것입니다.
관심 있는 분들은 TScan의 투자자 관계 웹사이트의 '이벤트 및 발표' 섹션을 통해 웹캐스트에 접속할 수 있습니다. 발표 녹화는 이벤트 이후 90일 동안 회사 웹사이트에서 재생할 수 있습니다.
TScan Therapeutics (Nasdaq: TCRX), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapies cellulaires T à ingénierie TCR pour le traitement du cancer, a annoncé sa participation à la 3ème Conférence Virtuelle Annuelle sur la Thérapie Cellulaire H.C. Wainwright. L'entreprise participera à une discussion informelle prévue pour mardi 25 février 2025, à 10h00 heure de l'Est.
Les parties intéressées peuvent accéder au webinaire via la section 'Événements et Présentations' sur le site des relations investisseurs de TScan à l'adresse ir.tscan.com. L'enregistrement de la présentation sera disponible en replay sur le site de l'entreprise pendant 90 jours après l'événement.
TScan Therapeutics (Nasdaq: TCRX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf TCR-engineered T-Zelltherapien zur Krebsbehandlung spezialisiert hat, hat seine Teilnahme an der 3. Virtuellen Jahrestagung zur Zelltherapie H.C. Wainwright angekündigt. Das Unternehmen wird an einem informellen Gespräch teilnehmen, das für Dienstag, den 25. Februar 2025, um 10:00 Uhr Eastern Time geplant ist.
Interessierte Parteien können über den Abschnitt 'Veranstaltungen und Präsentationen' auf der Investor-Relations-Website von TScan unter ir.tscan.com auf den Webcast zugreifen. Die Aufzeichnung der Präsentation bleibt 90 Tage nach der Veranstaltung auf der Website des Unternehmens verfügbar.
- None.
- None.
WALTHAM, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25, 2025 at 10:00 a.m. Eastern Time.
A webcast of the fireside chat will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 90 days following the event.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA™ Phase 1 heme trial). The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers (the PLEXI-TTM Phase 1 solid tumor trial). The Company is currently enrolling patients into both clinical programs.
Contacts
Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com
Maghan Meyers
Argot Partners
212-600-1902
TScan@argotpartners.com
FAQ
When is TScan Therapeutics (TCRX) presenting at the H.C. Wainwright Cell Therapy Conference 2025?
How long will TScan Therapeutics' (TCRX) conference webcast be available for replay?
Where can investors watch TScan Therapeutics' (TCRX) H.C. Wainwright conference presentation?
What type of presentation will TScan Therapeutics (TCRX) give at the H.C. Wainwright conference?
